HK Stock Market Move | INSILICO (03696) rose over 5% as the chairman of the board proposed to increase shareholding. Citigroup indicates that the company's proprietary platform could generate exponential value.

INSILICO (03696) has risen over 5%. As of the time of writing, it is up 4.98%, trading at HKD 49.34, with a turnover of HKD 580 million. On September 4, INSILICO announced that based on confidence in the company's future development prospects and recognition of its long-term investment value, the company's Chairman of the Board, Executive Director, Chief Executive Officer, and Chief Business Officer Aleksandrs Zavoronkovs, in compliance with the Securities Listing Rules of The Stock Exchange of Hong Kong Limited and other applicable laws and regulations, has initiated a plan to use his personal funds to purchase additional shares of the company in the open market. The share purchases will take place within September 2026, with a maximum estimated total of HKD 16 million. Previously, Mr. Zavoronkovs had also invested in the company's Series D funding round in 2022. Citi released a research report indicating that market research data shows global pharmaceutical R&D investment is estimated to be approximately USD 313 billion in 2026, with an AIDD penetration rate of only about 6%. Citi believes there is significant market growth potential and predicts that the global AI drug discovery ecosystem could reach approximately USD 50 billion by 2030, primarily focused on three areas: data generation, wet lab validation, and AI-native discovery. The bank believes that INSILICO, as a hybrid enterprise with both platform and pipeline capabilities, has an AIDD proprietary platform that can continuously generate "higher quality and differentiated" clinical assets, creating exponential value.